One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)
Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, announced today the closing of an oversubscribed 153 million SEK (€13.9 million) private placement financing round supported by current and new investors and private Swedish family offices. One-carbon Therapeutics will use the net proceeds from the private placement to […]
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering a novel cancer therapy, today announced that the first subject has been successfully dosed in its ODIN Phase 1/2 clinical trial (NCT07151040) evaluating TH9619, a first-in-class MTHFD1/2 inhibitor. This milestone was achieved at START Madrid/Fundación Jiménez Díaz University Hospital, under the supervision of Dr. Victor Moreno, Director […]
One-carbon Therapeutics AB announces the addition of multiple international experts to its Scientific Advisory Board
Professor Johann de Bono, Head of the Division of Clinical Studies and Drug Development Unit and Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK. Professor Timothy Yap, Vice President and Head of Clinical Development in the Therapeutics Discovery Division, The Institute for Applied Cancer Science MD […]
We will be in Copenhagen for the NLS days 29-30 November
We look forward to meeting you there!
Trick or trap by One Carbon Therapeutics
Read a short story of One-carbon Therapeutics achievements so far in Nature Biopharma Dealmakers (https://www.nature.com/articles/d43747-023-00079-z). We are working hard to bring our novel inhibitor into the clinic.
We are selected as the EIT Health’s Catapult 2022-2023 runner-up finalist
We look forward to showcasing our innovative approach targeting difficult to treat cancers at the 2023 Bits & Pretzels Healthtech event in Munich 20-21 June.
We are presenting exciting progress about MTHFD1/2 inhibitors at BIO International in Boston
You can listen to our company presentation on Monday, June 5 and during the 12th International Cancer Cluster Showcase satellite symposium at BIO.
One Carbon Therapeutics has been selected to present the MTHFD1/2 project to the International Board of MATWIN on May 10-11 th
We are excited to discuss our science and program with major pharma leaders.
Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism
The One-carbon Therapeutics team is proud and excited to share our latest paper published inNature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitorTH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificityand emphasises the importance of utilising correct human-like conditions and cancer models in drugdevelopment. We show that cancer-specific […]
We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit
We are presenting our data at the DDR inhibitor summit, January 24 – 26, 2023, Boston, USWe are excited to hear about the newest progress in the DDR field and look forward to all interestingdiscussions.